COSMO PHARMACEUT. EO-,26/ NL0011832936 /
02/09/2024 17:20:01 | Chg. -1.0000 | Volume | Bid17:32:09 | Ask17:32:09 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
82.5000EUR | -1.20% | 0 Turnover: 0.0000 |
83.5000Bid Size: 20 | 86.0000Ask Size: 20 | 1.38 bill.EUR | 2.36% | 1,195.28 |
Assets
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 30.2000 | 28.6000 | 30.2000 | 29.3000 | 30.4800 | ||||||
Intangible Assets | 28.5000 | 35.5000 | 49.2000 | 26.6000 | 372.7300 | ||||||
Long-Term Investments | 93.8000 | 41.9000 | 53.9000 | 114.5000 | 49.0800 | ||||||
Fixed Assets | 300.7000 | 251.5000 | 282.8000 | 343.3000 | 529.7100 | ||||||
Inventories | 3.2000 | 3.9000 | 6.1000 | 5.7000 | 13.1200 | ||||||
Accounts Receivable | 13.2000 | 12.8000 | 16.5000 | 23 | 20.5100 | ||||||
Cash and Cash Equivalents | 144.9000 | 210.7000 | 110.4000 | 185.9000 | 198.5600 | ||||||
Current Assets | 197.3000 | 374.2000 | 302.4000 | 252.9000 | 275.8500 | ||||||
Total Assets | 498 | 625.7000 | 585.2000 | 596.2000 | 805.5600 |
Liabilities
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 11.3000 | 8.8000 | 7.8000 | 8.4000 | 11.5900 | ||||||
Long-term debt | 3.8000 | 157.6000 | 163.3000 | 165.2000 | 169.0300 | ||||||
Liabilities to Banks | 4.4000 | 158.1000 | 164.8000 | 168.1000 | - | ||||||
Provisions | 4.3000 | 7.5000 | 8.8000 | 6.3000 | - | ||||||
Liabilities | 27.9000 | 180.8000 | 191.4000 | 196 | 292.8800 | ||||||
Share Capital | 3.9000 | 3.9000 | 3.9000 | 3.9100 | - | ||||||
Total Equity | 470.1000 | 444.9000 | 393.7000 | 400.1000 | 505.2800 | ||||||
Minority Interests | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 7.4000 | ||||||
Total liabilities equity | 498 | 625.7000 | 585.2000 | 596.2000 | 805.5600 |
Income Statement
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 67.2000 | 65.6000 | 62.5000 | 60.9000 | 65.0700 | ||||||
Depreciation (total) | - | - | - | - | - | ||||||
Operating Result | -15.5000 | -16.6000 | -12.3000 | 6.9000 | 11.1000 | ||||||
Interest Income | - | - | - | - | -4.2900 | ||||||
Income Before Taxes | -32.4000 | -17.5000 | -21.2200 | -6.9000 | - | ||||||
Income Taxes | 0.0000 | -.6000 | -3.2000 | -1 | 2.3300 | ||||||
Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 1 | ||||||
Net Income | -32.4000 | -18 | -24.4000 | -7.9000 | 21.6700 |
Per Share
Cash Flow
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | -10 | -16.2000 | -17.6000 | 10.1000 | 15.2000 | ||||||
Cash Flow from Investing Activities | -22.3000 | -71.8000 | -48.7000 | 75.4000 | 24.8600 | ||||||
Cash Flow from Financing | 72.7000 | 144.4000 | -34.5000 | -11.9000 | -27.2500 | ||||||
Decrease / Increase in Cash | 40.4000 | 62.4000 | -102 | 76.5000 | - | ||||||
Employees | 301 | 306 | 234 | 265 | 290 |